PubMed Daily Triage Digest — 2026-07-28

Run: 2026-07-28T09:36:09Z · Attempt 3 (repair) · Schema v1.3
Date window: CRDT 2026-07-27 → 2026-07-28
Topics scanned: 10 | Articles reviewed: 109 | Candidates evaluated: 109
High priority: 10 | Standard: 11 | Low/archive: 0 | Unsolicited finds: 1
Run status: PARTIAL_SUCCESS (candidate PMID arrays partially reconstructed from retained articles)

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Novel Therapeutics: Immunotherapy, CAR-T, Targeted Therapy

[PMID 42508433] · Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in BCG-unresponsive NMIBC with CIS (BOND-003 Cohort C) · 10/10 🟠 NOVEL_TREATMENT
Phase 3 single-arm trial (n=112, 41 centres): 75% complete response at any time in BCG-unresponsive NMIBC+CIS—provides a bladder-sparing alternative to radical cystectomy in a high-unmet-need indication where dual-mechanism oncolytic immunotherapy is a novel class. (Lancet Oncol, 2026 Aug)

[PMID 42507431] · Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy: OUTMATCH Stage 2 RCT · 8/10 🟠 NOVEL_TREATMENT
Double-blind RCT (n=117): omalizumab superior to MOIT in ITT analysis (36% vs 19%; OR 2.6; p=0.03), but advantage largely driven by MOIT's 31% SAE rate vs 0%—directly informs shared decision-making between FDA-approved treatment modalities. (JAMA Pediatr, 2026 Jul 27)

Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

[PMID 42509573] · Circulating tumor DNA precision oncology in pediatric solid tumors — the INFORM experience · 10/10 🔴 EARLY_CANCER_DETECTION
Prospective multicenter observational (n=130 pediatric patients, INFORM registry): 95% sensitivity/specificity ctDNA detection in 93% of patients via optimized in silico score; entity-specific assay selection guidance—first prospective multicenter validation in pediatric oncology. (Genome Med, 2026 Jul 27)

AI/ML in Clinical Diagnostics and Imaging

[PMID 42509078] · MerMED-FM: Multimodal, Multi-Disease Medical Imaging Foundation Model · 9/10 🟢 NEAR_TERM_IMPLEMENTABLE
Model development & validation (3.3M images, 7 modalities, 31 datasets): AUROC 0.81–0.96 across all modalities using only 10% labeled data, outperforming single-specialty and general-domain foundation models—significant advance toward scalable cross-specialty clinical AI. (Lancet Digit Health, 2026)

Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk

[PMID 42509395] · GLP-1 receptor agonists in MASH: systematic review & meta-analysis (27 RCTs, n=2,687) · 9/10 🟠 NOVEL_TREATMENT
Largest pooled analysis of GLP-1 RAs in MASH: RR=2.56 for MASH resolution without fibrosis worsening; fibrosis benefit limited to multi-receptor agonists and >48-week interventions—provides actionable guidance for therapy selection at a critical regulatory juncture. (Hepatol Int, 2026 Jul 27)

[PMID 42508844] · PRESTIGE-AMI RCT — SGLT2 inhibitors do not reduce infarct size or promote LV remodeling post-AMI · 9/10 🟢 NEAR_TERM_IMPLEMENTABLE
Definitive CMR-validated RCT (n=200): empagliflozin showed no benefit on infarct size (p=0.92) or LV remodeling (p=0.40)—high-value negative result clarifying SGLT2 mechanism of cardioprotection; informs future acute cardiac trial design. (JACC Cardiovasc Interv, 2026 Jul 27)

[PMID 42508725] · SGLT2 inhibitors reduce lung cancer risk by 27% in COPD+T2DM: nationwide Korean cohort · 8/10 ⚪ PROMISING_PRELIMINARY
Population-based cohort (n=14,927, IPTW-adjusted, median 2.97 yr): HR 0.73 for lung cancer, HR 0.77 for COPD exacerbation, HR 0.81 for all-cause mortality vs sulfonylureas—novel chemopreventive signal requiring prospective validation. (Chest, 2026 Jul 27)

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

[PMID 42509253] · circN4BP2L2 as survival-promoting regulator in T-ALL via AGO2-circRNA profiling · 9/10 ⚪ PROMISING_PRELIMINARY
Mechanistic in vitro + patient validation (4 T-ALL cell lines, AGO2-RIP-seq): circN4BP2L2 knockdown reduces proliferation and increases apoptosis; patient data corroborates oncogenic role—first systematic AGO2-circRNA interactome in T-ALL, new therapeutic target. (Leukemia, 2026 Jul 27)

[PMID 42509256] · Cohesin haploinsufficiency + inv(16) cooperate via Fli1 in AML — novel druggable vulnerability · 9/10 ⚪ PROMISING_PRELIMINARY
Mouse model + scRNA-seq: Smc3 haploinsufficiency paradoxically accelerates inv(16)-AML by increasing Fli1 chromatin accessibility; Fli1 essential for AML maintenance—novel therapeutic target in cohesin-mutated CBF-AML. (Leukemia, 2026 Jul 27)

Rare Diseases with High Unmet Need

[PMID 42503698] · Sapropterin for ACTA2-MSMDS — First-in-Human Report ⚠️ Ultra-Rare · 8/10 🟠 NOVEL_TREATMENT
n-of-1 translational report (in silico → fibroblast → single pediatric patient): sapropterin restores ACTA2 p.R179H-disrupted actin polymerization in silico and in patient cells; off-label treatment showed cerebrovascular stabilization—first-in-human proof-of-concept for drug repurposing in a lethal ultra-rare vasculopathy. (Ann Clin Transl Neurol, 2026 Jul 26)

🟢⚪ STANDARD (5–7) — Top by Topic

Early Cancer Detection

• [PMID 42507708] · ALFAssay: neural network for fragmentomics-based ctDNA in breast cancer · 7/10 · Early Detection (PLoS Comput Biol)
• [PMID 42503933] · ctDNA GSTP1/SFRP2 multimodal model for early HCC vs cirrhosis · 6/10 · Early Detection (Zhonghua Yu Fang Yi Xue Za Zhi)

Novel Therapeutics

• [PMID 42508642] · CAR-based cellular therapies for autoimmune diseases: immune reset, clinical evidence · 7/10 · Treatment Innovation (Transplant Cell Ther)

Precision Oncology

• [PMID 42509447] · SCRUM-MONSTAR-CTC: AI + multi-omics CTC platform framework · 7/10 · Genomics/Precision Medicine (Int J Clin Oncol)

Rare Diseases

• [PMID 42508438] · GCIG Cervical Cancer Consensus 2026 — 16 consensus statements from 33 GCIG groups · 7/10 · Public Health (Lancet Oncol)
• [PMID 42506055] · Therapeutic advances in major NBIA disorders (PKAN, MPAN, BPAN, PLA2G6-AD) · 6/10 · Drug Development (Neurol Int)

Hematologic Malignancies

• [PMID 42509137] · Germline predisposition in MPNs: 8–27% yield in sporadic cases · 7/10 · Genomics/Precision Medicine (Semin Hematol)

Cardiometabolic

• [PMID 42508996] · TRIM RCT: 10-hour TRE shows no appetite/inflammation benefit vs usual eating (negative) · 6/10 · Prevention (Obesity)

Aging, Longevity, and Population Health

• [PMID 42507085] · POC5 deficiency: novel centrosomal metabolic disorder linking senescence + adipogenesis · 7/10 · Genomics/Precision Medicine (FASEB J)
• [PMID 42505344] · Environmental carcinogenesis as stochastic evolutionary failure of senescence-control systems · 6/10 · Prevention (Cells)

💡 UNSOLICITED FINDS

[PMID 42509586] · Validated 1-Year Mortality Prediction in Three-Vessel Disease PCI: TALENT trial SYNTAX Score recalibration · 6/10 · Diagnostics (Eur Heart J Qual Care Clin Outcomes)
Post-hoc analysis of TALENT RCT (n=1,548 three-vessel disease PCI): logistic clinical SYNTAX Score achieves AUC 0.716–0.744 vs anatomical SYNTAX AUC 0.629; recalibration improves model fit for contemporary PCI practice.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 4
• Early Detection: 3
• Genomics/Precision Medicine: 5
• Prevention: 3
• Diagnostics: 2
• Public Health: 1
• Drug Development: 2
• Other: 1

By evidence maturity:

• Potentially Practice-Changing: 2 (BOND-003 phase 3, GLP-1 MASH meta-analysis)
• Validated: 5
• Exploratory: 14

By watchlist topic (reviewed / HIGH / best score):

By source type: peer_reviewed 21 | preprint 0

Topics with zero HIGH articles today: cbc_ml_hematology (0 results), aging_longevity (best: 7/10)

🔧 RUN NOTES

• Attempt 3 repair: Repaired from attempt2 salvage bundle. All biomedical content (PMIDs, titles, scores, summaries, key findings, author lists) preserved. Schema fields corrected to v1.3 compliance: evidence_maturity, access_level, pipeline_priority, classification_confidence, species_model enum values normalized; matched_watchlist_topics, unsolicited_find, pipeline_ready, notes, source_db, source_type, record_dates, publication_type, priority_flag_code, priority_flag_label, record_id fields added or corrected; per_topic_stats and search_logs rebuilt with full required field set.
• cbc_ml_hematology: Returned zero results in 2026-07-27–28 CRDT window. No window expansion triggered (threshold is <5 relevant records across all topics, not per-topic).
• Deduplication: PMID 42509573 (INFORM ctDNA) matched both early_cancer_detection and precision_oncology; counted once in articles array with both topics in matched_watchlist_topics.
• Candidate PMID arrays: Full 15-candidate lists not available from prior attempt; candidate_pmids populated with retained article PMIDs only; coverage_complete=false for topics where full candidate list is incomplete.
• run_status=PARTIAL_SUCCESS due to incomplete candidate PMID array reconstruction from prior attempt; all articles fully reviewed and scored.